Pelvic Inflammatory Disease

Pelvic inflammatory disease (PID) is an umbrella term for infectious endometritis, salpingitis, and peritonitis arising from ascending infection of the upper genital tract, most often from Neisseria gonorrhoeae or Chlamydia trachomatis. Because anaerobic organisms are also frequently involved, effective empiric therapy needs to cover gram-negative facultative bacteria and streptococci as well as gonorrhea and chlamydia, with anaerobic coverage considered as well. Untreated or undertreated PID is a leading cause of preventable infertility and ectopic pregnancy, which is why treatment is started empirically and promptly rather than waiting for full culture confirmation.^[1]

• Lower abdominal or pelvic pain, often bilateral, is the dominant symptom.
• Abnormal vaginal discharge or bleeding.
• Dyspareunia.
• Fever may or may not be present — its absence does not exclude PID.
• On examination: cervical motion tenderness, uterine tenderness, or adnexal tenderness.
• Presentation ranges from mild and easily missed to severe, with peritoneal signs, high fever, and vomiting.

• Untreated or recently treated chlamydia or gonorrhea infection.
• New or multiple sexual partners.
• A history of prior PID.
• Recent instrumentation of the upper genital tract, including IUD insertion.
• Younger age and inconsistent barrier protection.

PID is largely a clinical diagnosis based on pelvic tenderness in a patient with a compatible history — do not wait for microbiological confirmation before starting treatment, given the stakes of undertreated disease. Test for gonorrhea and chlamydia (these results guide follow-up and partner management even though treatment starts empirically), and consider pregnancy testing to exclude ectopic pregnancy, which can mimic PID. Imaging (pelvic ultrasound) helps assess for tubo-ovarian abscess when the presentation is more severe or not responding as expected.

• Eradicate the causative organism(s) with empiric coverage broad enough for gonorrhea, chlamydia, gram-negative facultative bacteria, streptococci, and likely anaerobes.
• Resolve pain, fever, and other acute symptoms.
• Preserve fertility by treating promptly rather than waiting for full diagnostic confirmation.
• Prevent recurrence and long-term sequelae (chronic pelvic pain, ectopic pregnancy, infertility) through partner treatment and adequate initial therapy.

• Refer all recent (under 60 days) sexual partners for examination and treatment; treat partners empirically for chlamydia and/or gonorrhea.
• Advise no sexual contact for the patient or partner(s) until 1 week after treatment initiation.
• If the patient has an IUD, do not remove it before at least 2 doses of antimicrobial therapy have been given — premature removal does not improve outcomes and interrupts contraception unnecessarily.

• Reassess clinically within 48-72 hours of starting outpatient therapy — a patient who is not improving by then should be reassessed for hospitalization, an alternative diagnosis, or a resistant/atypical organism.
• Confirm partner treatment was completed.
• Follow up chlamydia and gonorrhea test results as they return, and adjust or extend therapy if results suggest an organism not well covered by the initial regimen.
• For a patient with a tubo-ovarian abscess, arrange follow-up imaging to confirm resolution.

1. Reassess hospitalization criteria — a patient failing outpatient therapy may need inpatient parenteral treatment.
2. Confirm adherence to the full outpatient regimen, including the often-overlooked metronidazole component.
3. Image (or re-image) to assess for tubo-ovarian abscess if not already done.
4. Broaden or adjust antibiotic coverage based on culture/NAAT results and clinical response, and involve an infectious disease specialist for a patient not responding to an adequate initial regimen.
5. Reassess partner treatment status, since ongoing untreated exposure prevents resolution.

• Waiting for microbiological confirmation before starting treatment — PID is a clinical diagnosis and prompt empiric therapy protects fertility.
• Omitting metronidazole from the outpatient regimen — it is a routine addition, not optional.
• Managing a pregnant patient with suspected PID as an outpatient — hospitalize instead.
• Using a fluoroquinolone-based regimen or doxycycline in a pregnant or breastfeeding patient.
• Removing an IUD immediately at diagnosis instead of after at least 2 doses of antimicrobial therapy.
• Treating the patient without arranging partner examination and empiric treatment.

How to use this table: Ensure empiric coverage for N. gonorrhoeae, C. trachomatis, gram-negative facultative bacteria, and streptococci, with anaerobic coverage considered. Doses are adult doses and require patient-specific confirmation, including renal adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Outpatient Regimens

Cephalosporin-Based (preferred outpatient)

The PID-specific ceftriaxone dose (250 mg) differs from the 500 mg used for uncomplicated gonorrhea — see Choose Initial Treatment for why.

Fluoroquinolone-Based (alternative outpatient)

Contraindicated in pregnancy and breastfeeding.

Inpatient Regimens

Aminoglycoside + Lincosamide (preferred inpatient)

Preferred inpatient regimen; also the practical choice in pregnancy since it avoids fluoroquinolones and tetracyclines.

Cephalosporin-Based (alternative inpatient)

Doxycycline component is contraindicated in pregnancy and breastfeeding.

Fluoroquinolone-Based (alternative inpatient)

Contraindicated in pregnancy and breastfeeding.

Evidence note: Drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice per current PHAC guidance where it addresses PID specifically.^[1]